摘要
背景与目的：直肠癌全系膜切除术（TME）的应用显著改善了中高位直肠癌患者的预后,但是对影响局部复发的危险因素仍然有待进一步研究。本研究对行根治性TME手术的进展期直肠癌患者的临床病理资料和免疫组化资料进行分析,进一步探索影响局部复发的高危因素。方法：分析179例行TME手术的Ⅱ、Ⅲ期直肠癌患者临床病理资料以及免疫组化检测CD44v6表达水平和预后之间的关系。结果：所有患者随访1-90个月,中位随访57个月。5年生存率和5年无病生存率分别为66.75%和65.77%。CD44v6和淋巴结转移状况是与总的生存时间和无病生存时间均相关的独立的预后危险因素。CD44v6表达水平是影响Ⅲ期直肠癌患者局部复发的独立危险因素。结论：CD44v6是预测Ⅲ期直肠癌TME术后局部复发的重要分子标记物。
Background and purpose： Total mesorectal excision （TME） is the standard surgical procedure for resectable rectal cancer located 5 cm above the anal verge, but local recurrence is still a great challenge. The aim of the study was to explore the significance of CD44v6 expression as a prognostic marker for local recurrence of the patients with locally advanced rectal cancer after TME. Methods： 179 AJCC stage Ⅱ and Ⅲ rectal cancer patients were analyzed, and 179 paraffin-embedded tumor specimens were examined for the expression of CD44v6 to evaluate the relationship between clinicopathological variables and prognosis. Results： Median follow-up was 57 months. Five-year overall survival rate and diseasefree survival rate were 66.75% and 65.77%, respectively. CD44v6 expression, along with lymphnode metastasis was independent variables predicting prognosis. CD44v6 expression was the only independent biological marker predicting local recurrence for stage Ⅲ rectal cancers after TME treatment. Conclusions： CD44v6 expression was an important biological marker in terms of predicting local recurrence in stage Ⅲ rectal cancer patients ＇after the treatment by total mesorectal excision.
出处
《中国癌症杂志》
CAS
CSCD
2007年第7期552-555,559,共5页
China Oncology
关键词
直肠癌
TME
免疫组化
CD44V6
局部复发
预后
rectal cancer
total mesorectal excision, TME
immunohistochemistry
CD44v6
local recurrence
prognosis
